Background/Objectives: The recent guideline for intraductal papillary mucinous neoplasms (IPMNs) focuses on morphological features of the lesion as signs of malignant transformation, but ignores the background pancreatic parenchyma, including features of chronic pancreatitis (CP), which is a risk factor for pancreatic malignancies. Endoscopic ultrasonography frequently reveals evidence of CP (EUS-CP findings) in the background pancreatic parenchyma of patients with IPMNs. Therefore, we investigated whether background EUS-CP findings were associated with malignant IPMN. Methods: The clinical data of 69 consecutive patients with IPMNs who underwent preoperative EUS and surgical resection between April 2010 and October 2014 were collected prospectively. The association of EUS-CP findings (total number of EUS-CP findings; 0 vs. ≥1) with invasive IPMN was examined. The association of EUS-CP findings with pathological changes of the background pancreatic parenchyma (atrophy/inflammation/fibrosis) was also examined. Results: Among patients with EUS-CP findings, invasive intraductal papillary mucinous carcinoma (IPMC) was significantly more frequent than among patients without EUS-CP findings (42.5% [17/40] vs. 3.4% [1/29], p = 0.0002). In addition, patients with EUS-CP findings had higher grades of pancreatic atrophy and inflammation than patients without EUS-CP findings (atrophy: 72.5% [29/40] vs. 34.5% [10/29], p = 0.003; inflammation: 45.0% [18/40] vs. 20.7% [6/29], p = 0.04). Conclusions: In IPMN patients, detection of EUS-CP findings in the background pancreatic parenchyma was associated with a higher prevalence of invasive IPMC. Accordingly, EUS examination should not only assess the morphological features of the lesion itself, but also EUS-CP findings in the background parenchyma.

Keywords:
Chronic pancreatitis, Endoscopic ultrasonography, Intraductal papillary mucinous neoplasm, Pancreatic parenchyma
1.
Retter J, Dinter D, Bersch C, Singer MV, Lohr M: Acute recurrent pancreatitis curtaining an intraductal papillary mucinous tumor of the pancreas. J Gastrointestin Liver Dis 2007;16:445-447.
2.
Kloppel G: Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas. Hepatogastroenterology 1998;45:1981-1985.
3.
Tanaka M, Fernandez-del Castillo C, Adsay V, et al: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-197.
4.
Mimura T, Masuda A, Matsumoto I, et al: Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas. J Clin Gastroenterol 2010;44:e224-e229.
5.
Crippa S, Fernandez-Del Castillo C, Salvia R, et al: Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 2010;8:213-219.
6.
Suzuki Y, Atomi Y, Sugiyama M, et al: Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 2004;28:241-246.
7.
Rodriguez JR, Salvia R, Crippa S, et al: Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007;133:72-79; quiz 309-310.
8.
Aso T, Ohtsuka T, Matsunaga T, et al: “High-risk stigmata” of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2014;43:1239-1243.
9.
Ohno E, Hirooka Y, Itoh A, et al: Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Ann Surg 2009;249:628-634.
10.
Buscaglia JM, Shin EJ, Giday SA, et al: Awareness of guidelines and trends in the management of suspected pancreatic cystic neoplasms: survey results among general gastroenterologists and EUS specialists. Gastrointest Endosc 2009;69:813-820; quiz 820.e1-e17.
11.
Ridtitid W, DeWitt JM, Schmidt CM, et al: Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes. Gastrointest Endosc 2016;84:436-445.
12.
Yamamoto N, Kato H, Tomoda T, et al: Contrast-enhanced harmonic endoscopic ultrasonography with time-intensity curve analysis for intraductal papillary mucinous neoplasms of the pancreas. Endoscopy 2016;48:26-34.
13.
Kitano M, Kamata K, Imai H, et al: Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliary diseases. Dig Endosc 2015;27(suppl 1):60-67.
14.
Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433-1437.
15.
Talamini G, Falconi M, Bassi C, et al: Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999;94:1253-1260.
16.
Malka D, Hammel P, Maire F, et al: Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002;51:849-852.
17.
Catalano MF, Sahai A, Levy M, et al: EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc 2009;69:1251-1261.
18.
Majumder S, Chari ST: Chronic pancreatitis. Lancet 2016;387:1957-1966.
19.
Kume K, Masamune A, Ariga H, Shimosegawa T: Alcohol consumption and the risk for developing pancreatitis: a case-control study in Japan. Pancreas 2015;44:53-58.
20.
Ye W, Lagergren J, Weiderpass E, Nyren O, Adami HO, Ekbom A: Alcohol abuse and the risk of pancreatic cancer. Gut 2002;51:236-239.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.